Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06963034 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

StatusRecruiting
PhasePhase 3
Started2025-05-08
View on ClinicalTrials.gov ↗

Amendment history

2026-03-05
Study Status, Contacts/Locations, IPDSharing v9
Study sites20→21
2026-02-10
Study Status, Contacts/Locations v8
Study sites19→20
2025-12-12
Study Status, Contacts/Locations v7
Study sites18→19
2025-10-22
Study Status, Contacts/Locations v6
Study sites16→18
2025-09-19
Study Status, Contacts/Locations v5
Study sites15→16
Show 4 earlier versions
2025-09-04
Study Status, Contacts/Locations v4
Study sites11→15
2025-07-29
Study Status, Contacts/Locations v3
Study sites6→11
2025-06-25
Study Status, Oversight, Contacts/Locations, IPDSharing v2
Start dateestimated 2025-05→confirmed 2025-05-08
Study sites5→6
2025-05-21
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sites0→5
2025-04-30
Original filing
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Trial Details
NCT Number NCT06963034
Lead Sponsor Neurocrine Biosciences
Conditions Schizophrenia
Enrollment 284 participants
Start Date 2025-05-08
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-06